Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Transplantation Solid-organ transplantation

Williams JW, Mital D, Chong A, et al. Experiences with leflunonude in solid organ transplantation. Transplantation 2002 73 358-366. [Pg.1642]

Grieff M, Loertscher R, Shohaib SA, Stewart DJ. Cyclosporine-induced elevation in circulating endothelin-1 in patients with solid-organ transplants. Transplantation 1993 56 880-884. [Pg.437]

Describe common reasons for the various solid-organ transplants. [Pg.829]

SCr, serum creatinine SRL, sirolimus TAC, tacrolimus. (Reprinted from Johnson HJ, Schonder KS. Solid-organ transplantation. [Pg.839]

Solid-organ transplant recipients are at increased risk of infectious diseases, which is a major cause of early morbidity and mortality. The prevalence of posttransplant infection depends... [Pg.845]

Fungal infections are an important cause of morbidity and mortality in solid-organ transplant recipients. Immunologic (e.g.,... [Pg.846]

Successful outcomes in solid-organ transplantation generally are measured in terms of several separate end points (1) preventing acute rejection (2) increasing 1-year graft survival ... [Pg.850]

Solid organ transplant recipients have a blunted immune response to vaccines because the immunosuppressive regimens used to prevent organ rejection inhibit both T- and B-cell proliferation. Many of these patients will also have secondary hypogammaglobulinemia post-transplantation. Prior to transplant, children should complete primary immunization schedules if possible accelerated schedules may be used. Adults should have all vaccinations updated prior to transplantation.16... [Pg.1249]

Solid Organ Transplant Children s Healthcare of Atlanta-Egleston and Emory University Hospital Atlanta, Georgia... [Pg.1702]

Chap. 52 - Solid-Organ Transplantation Universal Program Number 014-999-07-067-H04... [Pg.1709]

Solid-organ transplantation Liver transplantation Micafungin 50 mg (1 mg/kg in patients under 50 kg) IV daily Patients with two or more key risk factor Amphotericin B IV 10-20 mg daily or Liposomal amphotericin B (AmBisome) 1 mg/kg/day or flucona-... [Pg.436]

FI. Field, H., and Garovoy, M. R., Positive impact of DNA typing on solid organ transplantation. [Pg.35]

See other pages where Transplantation Solid-organ transplantation is mentioned: [Pg.234]    [Pg.829]    [Pg.830]    [Pg.831]    [Pg.833]    [Pg.835]    [Pg.835]    [Pg.837]    [Pg.839]    [Pg.843]    [Pg.845]    [Pg.847]    [Pg.849]    [Pg.851]    [Pg.1034]    [Pg.1043]    [Pg.1205]    [Pg.1373]    [Pg.1449]    [Pg.1688]    [Pg.1692]    [Pg.141]    [Pg.380]    [Pg.130]    [Pg.354]   


SEARCH



Cyclosporine solid organ transplantation

Immunocompromised patient infection Solid-organ transplantation

Immunosuppressants solid organ transplant

Organ transplantation

Solid organ transplant

Solid organ transplant

Solid organ transplant rejection

Solid-organ transplant patient

Solid-organ transplant patient infections

Solid-organ transplant patient prevention

Solid-organ transplant patient types

Solid-organ transplantation

Solid-organ transplantation acute rejection

Solid-organ transplantation cancer

Solid-organ transplantation complications

Solid-organ transplantation evaluation

Solid-organ transplantation graft rejection

Solid-organ transplantation immunosuppressive therapy

Solid-organ transplantation infections

Solid-organ transplantation specific organs

Transplanted organ

© 2024 chempedia.info